Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Entera Bio (ENTX) Non Operating Income (2018 - 2025)

Entera Bio has reported Non Operating Income over the past 8 years, most recently at $26000.0 for Q4 2025.

  • For the quarter ending Q4 2025, Non Operating Income rose 471.43% year-over-year to $26000.0, compared with a TTM value of $90000.0 through Dec 2025, up 55.17%, and an annual FY2025 reading of $90000.0, up 55.17% over the prior year.
  • Non Operating Income came in at $26000.0 for Q4 2025, down from $56000.0 in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $60000.0 in Q2 2022 to a low of -$32000.0 in Q4 2023.
  • Median Non Operating Income over the past 5 years was $5000.0 (2023), compared with a mean of $10368.4.
  • The sharpest move saw Non Operating Income tumbled 275.0% in 2021, then skyrocketed 728.57% in 2022.
  • Over 5 years, Non Operating Income stood at -$27000.0 in 2021, then surged by 51.85% to -$13000.0 in 2022, then tumbled by 146.15% to -$32000.0 in 2023, then soared by 78.12% to -$7000.0 in 2024, then skyrocketed by 471.43% to $26000.0 in 2025.
  • Per Business Quant, the three most recent readings for ENTX's Non Operating Income are $26000.0 (Q4 2025), $56000.0 (Q3 2025), and $12000.0 (Q2 2025).